NoTOPain was a randomised, crossover, placebo controlled, double-blind, Phase II study of cetuximab in patients with treatment-refractory, non-malignant severe chronic neuropathic pain.  Neuropathic pain is a subtype of pain that can be caused by a variety of pathological processes that directly affect the sensory nervous system.

This trial was a proof of concept study with a single study site at the Sørlandet Sykehus, Kristiansand hospital in Norway. The Kristiansand hospital fulfilled the dual role of Sponsor and Investigator Site for this study.

Frontier Science undertook a wide scope of work for this study including randomisation; data management; collaboration in protocol development; statistical design, analysis and reporting and trial monitoring. Results have been published https://doi.org/10.1093/pm/pnz101.

 

OTHER PROJECTS

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

EPoS

EPoS

The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...

NordICC

NordICC

Colorectal cancer (CRC) is major burden in western countries which develops over a long time-interval from precursor lesions which exist in the colon. Colonoscopy can detect and remove the precursor lesions and may therefore be an effective intervention for the...

WORK WITH US

Frontier Science Scotland provides adaptable solutions across data management and biostatistics for clinical trials. To find out more, get in touch.

data management

biostatistics

quality